{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:32:26Z","timestamp":1793323946662,"version":"4.5.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and the involvement of multiple organ systems. The disease\u2019s heterogeneity challenges clinical assessment, highlighting the need for personalized diagnostics and therapies. Soluble immune checkpoint molecules (sICPs) have emerged as potential biomarkers for predicting disease activity in other autoimmune diseases. However, the role of sICPs in SLE has not yet been delineated. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study serum concentrations of soluble co-stimulatory (sCD25, sCD27, sCD40L, s4-1BB and sCD86) and co-inhibitory checkpoint molecules (sCTLA-4, sPD-1, sPD-L1, sPD-L2, sTim-3, sGal-9 and sLAG-3) were measured by bead-based assay in 235 SLE patients. sICPs were analyzed in relation to clinical data (SLEDAI, organ involvement, C3, C4, anti-dsDNA, Siglec- 1, and sustained DORIS\/LLDAS remission). Analyses included Wilcoxon rank-sum tests, multivariable logistic regressions, receiver operating characteristic (ROC) analyses, cluster analyses, and correlation matrices. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Higher concentrations of sCD25, sTim-3, and sGal-9 were associated with active SLE disease (SLEDAI &amp;gt; 4). Cluster analysis identified highest concentrations in a SLE subgroup with more severe disease (median SLEDAI 10). These molecules correlated strongly with each other and were specifically elevated in patients with renal involvement and\/ or anemia, but not with APS, skin, or joint manifestations. Low sCD25 levels were associated with sustained DORIS\/LLDAS remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights sCD25, sTim-3, and sGal-9 as biomarkers for active SLE and renal and hematologic involvement. Low sCD25 levels were associated with achieving long-term DORIS and LLDAS remission, underscoring the potential of sCD25 as a predictive and sensitive biomarker mandating further clinical validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1685275","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:31:24Z","timestamp":1758778284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE"],"prefix":"10.3389","volume":"16","author":[{"given":"L\u00e9a-Sophie","family":"Dreveton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Joachim","family":"Spencker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rincon-Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Aue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgin","family":"Osmanodja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheumatic Diseases"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Dorner","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1192","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"80","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222276","article-title":"Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades","volume":"81","author":"Duarte-Garc\u00eda","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1038\/s41598-021-85152-2","article-title":"Galectin-9 expression correlates with therapeutic effect in rheumatoid arthritis","volume":"11","author":"Sun","year":"2021","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13339","article-title":"Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis","volume":"43","author":"Yanaba","year":"2016","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-019-04506-4","article-title":"Serum soluble programmed cell death protein 1 could predict the current activity and severity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study","author":"Yoon","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"21319","DOI":"10.1038\/s41598-022-25466-x","article-title":"Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"12","author":"Pyo","year":"2022","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222479","article-title":"Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission","volume":"82","author":"Gamerith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000825","article-title":"Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus","volume":"33","author":"Stefanski","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3282","article-title":"and T-lymphocyte attenuator in systemic lupus erythematosus disease pathogenesis","volume":"116","author":"Vendel","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","article-title":"Immune checkpoint receptors in autoimmunity","volume":"80","author":"Burke","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"108647","DOI":"10.1016\/j.intimp.2022.108647","article-title":"An overview of immune checkpoint therapy in autoimmune diseases","volume":"107","author":"Mohammadi","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"New Engl J Med"},{"key":"B21","volume-title":"Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Phase 2b Trial in RA","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606","article-title":"A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B25","volume-title":"LEGENDplex\u2122 HU Immune Checkpoint Panel 1 Manual","year":""},{"key":"B26","volume-title":"R: A language and environment for statistical computing","year":"2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death ligand-1 (sPD-L1): A pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078","article-title":"Hematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 \u2013 IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v34i2.5369","article-title":"Biological role of the soluble interleukin-2 receptor in sarcoidosis","volume":"34","author":"Vanmaris","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007078","article-title":"Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus","volume":"13","author":"Ohmes","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicenter, double-blind, randomized and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B35","unstructured":"Nektar therapeutics announces phase 2 topline data for rezpegaldesleukin in patients with systemic lupus erythematosus\n          \n          \n          \n          2023"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318760993","article-title":"Serum soluble CD25 as a risk factor of renal impairment in systemic lupus erythematosus \u2014 a prospective cohort study","volume":"27","author":"Zhang","year":"2018","journal-title":"Lupus"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2250319","DOI":"10.1002\/eji.202250319","article-title":"Persistently active interferon-\u03b3 pathway and expansion of T-bet+ B cells in a subset of patients with childhood-onset systemic lupus erythematosus","volume":"53","author":"Moneta","year":"2023","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000576","article-title":"Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations","volume":"31","author":"Schrezenmeier","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003503","article-title":"PD-1\/PD-L1 governed cross-talk of exhausted CD8(+) T and memory B cells in systemic lupus erythematosus","volume":"10","author":"Wang","year":"2024","journal-title":"RMD Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111606","article-title":"Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus","volume":"41","author":"Guo","year":"2022","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.488478","article-title":"A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3) *","volume":"288","author":"M\u00f6ller-Hackbarth","year":"2013","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1665-4","article-title":"Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus","volume":"308","author":"Jiao","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.3390\/jcm9113563","article-title":"Serum levels of T cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic lupus erythematosus","volume":"9","author":"Asano","year":"2020","journal-title":"J Clin Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-013-0264-3","article-title":"Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients","volume":"14","author":"Guo","year":"2014","journal-title":"Clin Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227069","article-title":"Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus","volume":"15","author":"Matsuoka","year":"2020","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"van den Hoogen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.229","article-title":"Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids","volume":"39","author":"Lee","year":"2024","journal-title":"Korean J Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:31:27Z","timestamp":1758778287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2025.1685275"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1685275","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1685275"}}